| Toggle Summary
|
Minerva Neurosciences Announces Positive Data From Six-Month Extension of Phase IIb Trial of MIN-101 Monotherapy in Schizophrenia
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences Announces Acceptance of Presentations of Clinical Data With MIN-101 and MIN-117 at American College of Neuropsychopharmacology Annual Meeting
MIN-101 to be highlighted in oral presentation
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences Provides Update on MIN-101 and MIN-117 Clinical Programs
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences to Present at 23rd Annual NewsMakers in the Biotech Industry Conference on September 9, 2016
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences Reports Second Quarter 2016 Financial Results and Business Updates
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences to Report Second Quarter 2016 Financial Results and Business Updates on August 4, 2016
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences Set to Join Russell 3000® and Russell 2000® Indexes
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences to Present at JMP Securities Life Sciences Conference June 21, 2016
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences Announces Pricing of Public Offering of Common Stock
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences Announces Proposed Public Offering of Common Stock
|
View HTML
|
